Lenalidomide

• A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS Recruiting
  2023-505221-14-00 Phase II 5 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part… Recruiting
  2022-503092-28-00 Phase III 8 countries Regeneron Pharmaceuticals Inc.
• A Phase 2 Study of Teclistamab in Combination with Daratumumab or Lenalidomide in Elderly Patients with Newly Diagnosed Multiple Myeloma - I… Recruiting
  2024-514101-65-00 Phase II 1 country Centre Hospitalier Universitaire De Lille
• A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory… Recruiting
  2023-503206-37-00 Phase III 4 countries F. Hoffmann-La Roche AG
• Expression-linked and R-ISS-adapted stratification for first line therapy in multiple myeloma patients (ELIAS) Recruiting
  2022-500453-16-00 Phase II 1 country University Medical Centre Schleswig-Holstein
• Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting
  2022-501515-14-00 Phase III 16 countries Celgene Corp.
• MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient… Recruiting
  2022-501810-77-00 Phase III 5 countries Lysarc
• A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-,Talquetamab- and JNJ-79635322-based Combination Regimens in Participants wit… Recruiting
  2024-517382-17-00 Phase II 1 country Universitaetsklinikum Heidelberg AöR
• CO43923 Master Protocol: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients with Multiple Myeloma CO43923 Substud… Recruiting
  2023-504484-16-00 Phase I/II 4 countries F. Hoffmann-La Roche AG
• MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex… Recruiting
  2024-514139-50-00 Phase III 12 countries Pfizer Inc.
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination… Recruiting
  2023-503442-30-00 Phase III 14 countries Janssen - Cilag International
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia… Recruiting
  2023-510384-36-00 Phase III 13 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin… Recruiting
  2023-505347-38-00 Phase I/II 7 countries AbbVie Deutschland GmbH & Co. KG
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim… Recruiting
  2024-510690-16-00 Phase III 7 countries Epizyme Inc.
• IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre… Recruiting
  2024-517215-67-00 Phase III 1 country Centre Hospitalier Universitaire De Poitiers
• An early phase clinical trial to investigate EO2463, a novel cancer vaccine therapy, in patients with indolent Non-Hodgkin's Lymphoma. Recruiting
  2023-509254-58-00 Phase I (FiH) 3 countries Enterome
• A Phase 2, open-label study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple m… Ended
  2024-517020-18-00 Phase II 1 country Fundacion PETHEMA
• RElapse from Mrd Negativity As iNdication for Treatment Ended
  2023-510215-18-00 Phase II/III 2 countries Oslo University Hospital HF
• A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu… Ended
  2024-510965-41-00 Phase III 11 countries AbbVie Deutschland GmbH & Co. KG
• Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone… Ended
  2023-508310-41-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
• MTR² Ended
  2022-502790-42-00 Phase II 1 country University Of Cologne
• TALTEC: A phase II study measuring MRD negativity after bispecific T-cell redirectors TALquetamab and TEClistamab consolidation as part of f… Ended
  2023-508212-38-00 Phase II 3 countries North Estonia Medical Centre Foundation
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended
  2023-506906-38-00 Phase III 17 countries AbbVie Deutschland GmbH & Co. KG
• A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or… Ended
  2023-503452-27-00 Phase III 7 countries Novartis Pharma AG

Showing 25–48 of 97 trials